Abordajes y tratamientos contemporáneos para la esquizofrenia: Diagnóstico e Intervención Psiquiátrica
Resumen
El objetivo de este estudio de revisión y de análisis crítico, consistió en la elaboración de una completa matriz de datos, en la que se recolectaron más de 300 artículos científicos, los cuales se fueron decantando tras varios procedimientos de rigor, a saber: que fuesen estudios evaluados por Pares, que contaran con ensayos clínicos o experimentales, que la representación de la información contenida y los métodos estadísticos fuesen sofisticados y de la más alta calidad y representatividad. Se revisaron las Bases de Datos Científicas de mayor reconocimiento a nivel mundial, además, se logró hacer un análisis comparativo entre diferentes metodologías y distintos abordajes dedicados a la esquizofrenia, permitiendo generar un manuscrito, con un nivel muy alto de profundidad en materia del impacto que la psiquiatría ha tenido históricamente en el estudio de la esquizofrenia y sobre cómo podría alcanzar mejores procedimientos e intervenciones, si es que consigue hacer trabajos transdisciplinarios con otras ciencias de la salud
Descargas
Citas
Belvederi-Murri, M., & Amore, M. (2019). The Multiple Dimensions of Insight in Schizophrenia-Spectrum Disorders. Schizophrenia bulletin, 45(2), 277–283. https://doi.org/10.1093/schbul/sby092
Bueno-Antequera, J., & Munguía-Izquierdo, D. (2020). Exercise and Schizophrenia. Advances in experimental medicine and biology, 1228, 317–332. https://doi.org/10.1007/978-981-15-1792-1_21
Correll, C. U., & Howes, O. D. (2021). Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options. The Journal of clinical psychiatry, 82(5), MY20096AH1C. https://doi.org/10.4088/JCP.MY20096AH1C
Ding, J. B., & Hu, K. (2021). Cigarette Smoking and Schizophrenia: Etiology, Clinical, Pharmacological, and Treatment Implications. Schizophrenia research and treatment, 2021, 7698030. https://doi.org/10.1155/2021/7698030
Faden, J., & Citrome, L. (2019). Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment. Expert opinion on pharmacotherapy, 20(1), 11–24. https://doi.org/10.1080/14656566.2018.1543409
Falkai, P., & Schmitt, A. (2022). Failed regeneration and inflammation in schizophrenia: two sides of the same coin? Journal of neural transmission (Vienna, Austria : 1996), 10.1007/s00702-022-02496-3. Advance online publication. https://doi.org/10.1007/s00702-022-02496-3
Goh, K. K., Chen, C. H., & Lane, H. Y. (2021). Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment. International journal of molecular sciences, 22(4), 2146. https://doi.org/10.3390/ijms22042146
Gomes, F. V., & Grace, A. A. (2021). Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention. International journal of molecular sciences, 22(9), 4467. https://doi.org/10.3390/ijms22094467
Horan, W. P., & Green, M. F. (2019). Treatment of social cognition in schizophrenia: Current status and future directions. Schizophrenia research, 203, 3–11. https://doi.org/10.1016/j.schres.2017.07.013
Horowitz, M. A., Macaulay, A., & Taylor, D. (2022). Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia. JAMA psychiatry, 79(1), 83–85. https://doi.org/10.1001/jamapsychiatry.2021.3400
Kart, A., Özdel, K., & Türkçapar, M. H. (2021). Cognitive Behavioral Therapy in Treatment of Schizophrenia. Noro psikiyatri arsivi, 58(Suppl 1), S61–S65. https://doi.org/10.29399/npa.27418
Keshavan, M. S., Collin, G., Guimond, S., Kelly, S., Prasad, K. M., & Lizano, P. (2020). Neuroimaging in Schizophrenia. Neuroimaging clinics of North America, 30(1), 73–83. https://doi.org/10.1016/j.nic.2019.09.007
Kronick, J., Sabesan, P., Burhan, A. M., & Palaniyappan, L. (2021). Assessment of treatment resistance criteria in non-invasive brain stimulation studies of schizophrenia. Schizophrenia research, S0920-9964(21)00221-8. Advance online publication. https://doi.org/10.1016/j.schres.2021.06.009
Lefebvre, S., Pavlidou, A., & Walther, S. (2020). What is the potential of neurostimulation in the treatment of motor symptoms in schizophrenia?. Expert review of neurotherapeutics, 20(7), 697–706. https://doi.org/10.1080/14737175.2020.1775586
Leucht, S., & Davis, J. M. (2022). Which first-generation antipsychotics should be "repurposed" for the treatment of schizophrenia. European archives of psychiatry and clinical neuroscience, 272(1), 1–3. https://doi.org/10.1007/s00406-021-01378-1
Leucht, S., Siafis, S., & Davis, J. M. (2022). Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia-Reply. JAMA psychiatry, 79(1), 86–87. https://doi.org/10.1001/jamapsychiatry.2021.3403
Lisoway, A. J., Chen, C. C., Zai, C. C., Tiwari, A. K., & Kennedy, J. L. (2021). Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment. Schizophrenia research, 232, 112–124. https://doi.org/10.1016/j.schres.2021.05.010
Lobo, M. C., Whitehurst, T. S., Kaar, S. J., & Howes, O. D. (2022). New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neuroscience and biobehavioral reviews, 132, 324–361. https://doi.org/10.1016/j.neubiorev.2021.11.032
McCutcheon, R. A., Reis-Marques, T., & Howes, O. D. (2020). Schizophrenia-An Overview. JAMA psychiatry, 77(2), 201–210. https://doi.org/10.1001/jamapsychiatry.2019.3360
Meyer-Lindenberg, A., & Hirjak, D. (2022). Schizophrenia as a categorical diagnosis: A view from the neural risk architecture. Schizophrenia research, 242, 87–90. https://doi.org/10.1016/j.schres.2022.01.021
Nour, M. M., & Dolan, R. J. (2022). Synaptic Gain Abnormalities in Schizophrenia and the Potential Relevance for Cognition. Biological psychiatry, 91(2), 167–169. https://doi.org/10.1016/j.biopsych.2021.10.017
Nucifora, F. C., Jr, Woznica, E., Lee, B. J., Cascella, N., & Sawa, A. (2019). Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiology of disease, 131, 104257. https://doi.org/10.1016/j.nbd.2018.08.016
Patel, C., Huang, A., Wang, L., Paliwal, Y., & Joshi, K. (2022). Patient Journey of Veterans with Schizophrenia: An Analysis of Treatment Patterns, Healthcare Resource Utilization and Costs. Advances in therapy, 39(3), 1199–1214. https://doi.org/10.1007/s12325-021-01997-z
Radaic, A., & Martins-de-Souza, D. (2020). The state of the art of nanopsychiatry for schizophrenia diagnostics and treatment. Nanomedicine: nanotechnology, biology, and medicine, 28, 102222. https://doi.org/10.1016/j.nano.2020.102222
Torregrossa, L. J., Amedy, A., Roig, J., Prada, A., & Park, S. (2022). Interoceptive functioning in schizophrenia and schizotypy. Schizophrenia research, 239, 151–159. https://doi.org/10.1016/j.schres.2021.11.046
Vadukapuram, R., Trivedi, C., Shah, K., Mansuri, Z., & Reddy, A. (2022). The Promise of Predictive Biomarkers for Antipsychotic Efficacy: A Review of Peripheral microRNAs to Evaluate Schizophrenia Treatment Response. The primary care companion for CNS disorders, 24(2), 21nr03048. https://doi.org/10.4088/PCC.21nr03048
Werner, F. M., & Coveñas, R. (2021). Risk Genes in Schizophrenia and Their Importance in Choosing the Appropriate Antipsychotic Treatment. Current pharmaceutical design, 27(30), 3281–3292. https://doi.org/10.2174/1381612827666210215151333
Derechos de autor 2023 Nicolás Parra-Bolaños;Pedro Carlos Martínez Suárez;Luís Alfonso Velásquez Pérez
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.jpg)
